Aldeyra Therapeutics, Inc. ( ALDX ) NASDAQ Capital Market

Cena: 5.44 ( -1.63% )

Aktualizacja 07-24 22:00
NASDAQ Capital Market
Branża: Biotechnology

Notowania:


Opis firmy:

Aldeyra Therapeutics, Inc., firma biotechnologiczna, rozwija i komercjalizuje leki na choroby oka i ogólnoustrojowe za pośrednictwem odporności. Głównym kandydatem na produkt firmy jest Reproxalap, reaktywny modulator gatunków aldehydu (RASP), który jest w badaniu klinicznym fazy III w leczeniu chorób suchego oka i alergicznego zapalenia spojówek. Opracowuje również ADX-629, pierwszą w klasie doustnie podawanym modulatorem RASP, który jest badaniem klinicznym fazy II dla łuszczycy, astmy i Covid-19; oraz ADX-2191, inhibitor reduktazy dihydrofolianowej, który znajduje się w fazie 3 do zapobiegania proliferacyjnej witreoretynopatii i badania klinicznego fazy II w leczeniu pigmentacji zapalenia siatkówki, a także do leczenia pierwotnego limfaka witreoretynowego. Firma ma umowę licencyjną z Madrigal Pharmaceuticals, Inc. w celu opracowania ADX-1612, która hamuje dysze-białko w leczeniu chorób zapalnych. Firma była wcześniej znana jako Aldexa Therapeutics, Inc. i zmieniła nazwę na Aldeyra Therapeutics, Inc. w marcu 2014 r. Aldeyra Therapeutics, Inc. została włączona w 2004 roku i ma siedzibę w Lexington, Massachusetts.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 9
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 96.2438
Ilość akcji: Brak danych
Debiut giełdowy: 2014-05-02
WWW: https://www.aldeyra.com
CEO: Dr. Todd C. Brady M.D., Ph.D.
Adres: 131 Hartwell Avenue
Siedziba: 02421 Lexington
ISIN: US01438T1060
Wskaźniki finansowe
Kapitalizacja (USD) 325 832 064
Aktywa: 117 319 352
Cena: 5.44
Wskaźnik Altman Z-Score: 0.4
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -5.6
Ilość akcji w obrocie: 96%
Średni wolumen: 1 215 044
Ilość akcji 59 895 600
Wskaźniki finansowe
Przychody TTM 392 620
Zobowiązania: 32 223 648
Przedział 52 tyg.: 1.14 - 7.2
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -1.0
P/E branży: 26.1
Beta: 1.432
Raport okresowy: 2025-07-30
WWW: https://www.aldeyra.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Todd C. Brady M.D., Ph.D. Chief Executive Officer, President & Director 834 103 1972
Dr. Stephen G. Machatha Ph.D. Chief Development Officer 503 625 1977
Mr. Bruce M. Greenberg CPA, M.B.A. Senior Vice President of Finance, Interim Chief Financial Officer & Treasurer 429 825 1968
David Burke Head of Investor Relations 0 0
Lista ETF z ekspozycją na akcje Aldeyra Therapeutics, Inc.
Symbol ETF Ilość akcji Wartość
IWM 1 402 697 6 101 730
IWO 379 280 1 649 867
VTWO 249 247 535 881
VHT 139 257 299 402
IWC 119 458 519 642
DFAS 115 186 495 299
IWN 88 612 385 460
ITOT 84 887 369 258
PRFZ 61 507 264 480
GSSC 36 745 158 003
VFMO 34 654 199 260
VTWV 30 973 66 591
RSSL 28 430 128 503
QQQS 17 403 74 832
VMO.TO 16 849 139 437
IWV 14 391 62 599
XSU.TO 10 063 59 673
UWM 5 492 23 615
VTWG 4 743 10 197
URTY 4 559 19 603
XEQT.TO 3 170 18 799
VTHR 2 922 6 282
DFAU 2 575 11 072
XUU.TO 1 558 9 642
XBAL.TO 491 3 039
XUH.TO 221 962
XAW.TO 193 1 144
HDG 68 292
XCNS.TO 38 223
XTR.TO 9 39
SPXS.L 0 0
PZW.TO 0 0
Wiadomości dla Aldeyra Therapeutics, Inc.
Tytuł Treść Źródło Aktualizacja Link
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-16 13:00:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-14 13:00:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com 2025-05-13 17:22:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com 2025-05-12 21:46:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-10 12:00:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-08 12:00:00 Czytaj oryginał (ang.)
ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. accessnewswire.com 2025-05-07 20:07:00 Czytaj oryginał (ang.)
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX) NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. globenewswire.com 2025-05-07 12:46:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-07 12:00:00 Czytaj oryginał (ang.)
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. globenewswire.com 2025-05-06 20:42:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com 2025-05-06 20:02:00 Czytaj oryginał (ang.)
ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. accessnewswire.com 2025-05-06 19:48:00 Czytaj oryginał (ang.)
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. For the prespec. businesswire.com 2025-05-05 22:34:00 Czytaj oryginał (ang.)
ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. accessnewswire.com 2025-05-05 19:38:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com 2025-05-05 18:12:00 Czytaj oryginał (ang.)
ALDX SECURITIES ALERT: Lose Money on Aldeyra Therapeutics, Inc.? Contact BFA Law about Securities Investigation (NASDAQ:ALDX) NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. globenewswire.com 2025-05-05 11:53:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-03 14:00:00 Czytaj oryginał (ang.)
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law NEW YORK, May 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. globenewswire.com 2025-05-03 11:18:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-02 14:00:00 Czytaj oryginał (ang.)
ALDX INVESTIGATION ALERT: BFA Law Alerts Aldeyra Therapeutics, Inc. Investors of the Pending Securities Investigation -- Contact BFA Law if You Suffered Losses NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. accessnewswire.com 2025-05-02 11:42:00 Czytaj oryginał (ang.)